

Borch Publications

Stork, G. and Borch, R. A new synthesis of 1,4- and 1,5-diketones. *J. Am. Chem. Soc.* 86: 935, 1964.

Stork, G. and Borch, R. A synthesis of cis-Jasmone. *J. Am. Chem. Soc.* 86: 936, 1964.

Borch, R.F. A new method for the reduction of secondary and tertiary amides. *Tetrahedron Lett.* 61, 1968.

Borch, R.F. The reduction of nitrilium salts. *Chem. Commun.* 442, 1968.

Borch, R.F. Alkoxy-carbonium ions. The structure of O-alkylated esters. *J. Am. Chem. Soc.* 90: 5303, 1968.

Borch, R.F. Nitrilium salts. A new method for the synthesis of secondary amines. *J. Org. Chem.* 34: 627, 1969.

Borch, R.F. and Fields, D.L. Wolff rearrangement of 1,3-bis-diazo-2-decalones. *J. Org. Chem.* 34: 1480, 1969.

Goldberg, I.B., Bolton, J.R. and Borch, R.F. The synthesis of 1-2, 6-7-dibenzopyrene from biphenylene and lithium. *Chem. Commun.* 223, 1969.

Borch, R.F. and Durst, H.D. Lithium cyanoborohydride, a versatile new reagent. *J. Am. Chem. Soc.* 91: 3996, 1969.

Borch, R.F., Bernstein, M.D. and Durst, H.D. The cyanohydrinborate anion as a selective reducing agent. *J. Am. Chem. Soc.* 93: 2897, 1971.

Borch, R.F., Crocker, J.F.S., Brown, D.M. and Vernier, R.L. Renal cystic disease in newborn rats induced by diphenylamine derivatives. *Am. J. Pathol.* 60: 343, 1972.

Borch, R.F., Levitan, S.R. and Van-Catledge, F.A. The reaction of acyl cyanides with grignard reagents. *J. Org. Chem.* 37: 726, 1972.

Borch, R.F., Grudzinskas, C.V., Peterson, D.A. and Weber, L.D. A new synthesis of 2(1H)pyridones. Synthesis of a potential camptothecin intermediate. *J. Org. Chem.* 37: 1141, 1972.

Borch, R.F. Reductive amination with sodium cyanoborohydride; N,N-dimethyl cyclohexylamine. *Org. Syntheses* 52: 124, 1972.

Borch, R.F. and Hassid, A.I. A new method for the methylation of amines. *J. Org. Chem.* 37: 1673, 1972.

Borch, R.F. and Levitan, S.R. An asymmetric synthesis of alcohols, amines, and amino acids. *J. Org. Chem.* 37: 2347, 1972.

Borch, R.F. A new procedure for the Darzens synthesis of glycidic esters. *Tetrahedron Lett.* 3761, 1972.

Borch, R.F. and Newell, R.G. A novel synthesis of 2-oxo-1,2,3,4-tetrahydrocarbazoles. *J. Org. Chem.* 38: 2729, 1973.

Borch, R.F. Separation of long-chain fatty acids as phenacyl esters by high pressure liquid chromatography. *Anal. Chem.* 47: 2437, 1975.

Borch, R.F., Evans, A.J. and Wade, J.J. Diene isomerization in a Diels Alder reaction. The synthesis of 8-*epi*-Dendrobine. *J. Am. Chem. Soc.* 97: 6282, 1975.

Borch, R.F. and Ho, B.C. A new synthesis of the pyrrolizidine alkaloids (\pm)-Isoretronecanol and (\pm)-Trachelanthamidine. *J. Org. Chem.* 42, 1225, 1977.

Borch, R.F., Evans, A.J. and Wade, J.J. Synthesis of 8-*epi*-Dendrobine. *J. Am. Chem. Soc.* 99, 1612 (1977).

Borch, R.F., Markovitz, J.H. and Pleasants, M.E. A new method for the HPLC analysis of Pt(II) in urine. *Anal. Lett.* 12(B): 917, 1979.

Borch, R.F. and Pleasants, M.E. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. *Proc. Natl. Acad. Sci.* 76: 6611, 1979.

Borch, R.F., Katz, J.C., Lieder, P.H. and Pleasants, M.E. Effect of diethyldithiocarbamate rescue on tumor responses to cis-platinum in a rat model. *Proc. Natl. Acad. Sci.* 77: 5441, 1980.

Low, J.E., Borch, R.F. and Sladek, N.E. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramidate mustard and acrolein mediated by bifunctional catalysts. *Cancer Res.* 42: 830, 1982.

Hrushesky, W.J.M., Borch, R.F. and Levi, F. A circadian time dependence of cisplatin urinary pharmacokinetics. *Clin. Pharmacol. Ther.* 32: 330, 1982.

Levi, F., Hrushesky, W.J.M., Borch, R.F., Pleasants, M.E., Kennedy, B.J. and Halberg, F. Cisplatin urinary pharmacokinetics and nephrotoxicity: A common circadian mechanism. *Cancer Treat. Rep.* 66: 1933, 1982.

Sladek, N.E., Smith, P.C., Bratt, P.M., Low, J.E., Powers, J.F., Borch, R.F. and Coveney, J.R. Influence of diuretics on urinary bifunctional catalytic activity and cyclophosphamide-induced bladder toxicity. *Cancer Treat. Rep.* 66: 1889, 1982.

Low, J.E., Borch, R.F. and Sladek, N.E. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. *Cancer Res.* 43: 4815, 1983.

Borch, R.F., Bodenner, D.L. and Katz, J.C. Diethyldithiocarbamate and cisplatin toxicity. In: M.P. Hacker, E.B. Douple and I.H. Krakoff, eds., Platinum Coordination Complexes in Cancer Chemotherapy, pp. 154-164. Boston: Martinus-Nijhoff, 1984.

Borch, R.F. and Getman, K.M. Base-catalyzed hydrolysis of 4-hydroperoxy- cyclophosphamide: Evidence for iminocyclophosphamide as an intermediate. *J. Med. Chem.* 27: 485, 1984.

Borch, R.F., Hoye, T.R. and Swanson, T.A. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: ^1H and ^{31}P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution. *J. Med. Chem.* 27: 490, 1984.

Borch, R.F. and Lieder, P.H. Triethyloxonium tetrafluoroborate derivatization and HPLC analysis of diethyldithiocarbamate in plasma. *Anal. Lett.* 18(B1): 57, 1985.

Clark, C., LaSota, I. and Borch, R.F. Evidence that X-irradiation and 4-hydroperoxycyclophosphamide affects different lymphocytes that respond to specific antigen in vitro. *J. Leukocyte Biol.* 37: 175, 1985.

Yamamoto, J.K. and Borch, R.F. Photoconversion of 7-dehydrocholesterol to vitamin D in synthetic phospholipid bilayers. *Biochem.* 24: 3338, 1985.

Dohn, D.R., Quebbemann, A.J., Borch, R.F. and Anders, M.W. Enzymatic reaction of chlorotrifluoroethene with glutathione: ^{19}F NMR evidence for stereochemical control of the reaction. *Biochem.* 24: 5137, 1985.

Bodenner, D.L., Dedon, P.C., Keng, P.C., Katz, J.C. and Borch, R.F. Selective protection against cis-dichlorodiammine platinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. *Cancer Res.* 46: 2751, 1986.

Bodenner, D.L., Dedon, P.C., Keng, P.C. and Borch, R.F. Effect of diethyldithiocarbamate on cis-platinum-induced cytotoxicity, DNA cross-linking, and g-glutamyl transpeptidase inhibition. *Cancer Res.* 46: 2745, 1986.

Dedon, P.C., Qazi, R. and Borch, R.F. Potential mechanisms of cisplatin toxicity and diethyldithiocarbamate rescue. In: D.C.H. McBrien, ed., Biochemical Mechanisms of Platinum Antitumor Drugs, pp. 199-225. Oxford: IRL Press, 1986.

Borch, R.F. The platinum anti-tumor drugs. In: R.A. Prough and G. Powis, eds., Metabolism and Action of Anti-Cancer Drugs, pp. 163-193. London: Taylor and Francis, 1987.

Borch, R.F. and Millard, J.A. The mechanism of activation of 4-hydroxycyclophosphamide. *J. Med. Chem.* 30: 427, 1987.

Kwon, C.-H., Borch, R.F., Engel, J. and Niemeyer, U. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism. *J. Med. Chem.* 30: 395, 1987.

Kwon, C.-H. and Borch, R.F. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. *Cancer Res.* 47: 1505, 1987.

Dedon, P.C. and Borch, R.F. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. *Biochem. Pharmacol.* 36: 1955, 1987.

Clark, C., LaSota, I. and Borch, R.F. Low-dose X-irradiation and 4-hydroperoxy cyclophosphamide distinguishes three IyT-1^+ and lymph node T-cell subtypes that respond to specific antigen in vitro. *J. Leukocyte Biol.* 41: 330, 1987.

Kwon, C.-H., Kirk, M.C., Struck, R.F. and Borch, R.F. Spectroscopic detection of imino cyclophosphamide and its possible role in cyclophosphamide metabolism. *J. Med. Chem.* 30: 1110, 1987.

Borch, R.F., Dedon, P.C. and Montine, T.J. Experimental approaches to reducing platinum induced kidney toxicity. In: J.S. Lazo and T.R. Tritton, eds., Organ Directed Toxicities of Anticancer Drugs, pp. 190-202. Boston: Martinus Nijhoff, 1988.

Borch, R.F., Dedon, P.C., Gringeri, A. and Montine, T.J. Inhibition of platinum drug toxicity by diethyldithiocarbamate. In: M. Nicolini, ed., Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 216-227. Boston: Martinus Nijhoff, (1988).

Montine, T.J. and Borch, R.F. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. *Cancer Res.* 48: 6017, 1988.

Gandara, D.R., Perez, E.A., DeGregorio, M.W., Borch, R.F. Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue. *J. Clin. Oncol.* 6, 1785, 1988.

Qazi, R., Chang, A.Y.C., Borch, R.F., Montine, T., Dedon, P., Loughner, J. and Bennett, J.M. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector of cisplatin toxicity. *J. Natl. Cancer Inst.* 80: 1486, 1988.

Gringeri, A., Keng, P.C. and Borch, R.F. Diethyldithiocarbamate inhibition of bone marrow toxicity caused by cisplatin or carboplatin. *Cancer Res.* 48: 5708, 1988.

Borch, R.F. and Markman, M. Biochemical modulation of cisplatin toxicity. *Pharmacol. Ther.* 41: 371, 1989.

DeGregorio, M.W., Gandara, D.R., Holleran, W.M., Perez, E.A., King, C.C., Wold, H.G., Montine, T.J. and Borch, R.F. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: Preliminary pharmacologic observations. *Cancer Chemother. Pharmacol.* 23: 276, 1989.

Schmalbach, T.K. and Borch, R.F. Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice. *Cancer Res.* 49: 2574, 1989.

Kwon, C.-H. and Borch, R.F. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogs. *J. Med. Chem.* 32: 1491, 1989.

Rodewald, L.E., Maiman, L.A., Foye, H.R., Borch, R.F. and Forbes, G.B. Deuterium oxide as a tracer for compliance measurement in pediatric clinical drug trials. *J. Pediatrics* 114: 885, 1989.

Schmalbach, T.K. and Borch, R.F. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine (cyclobutanedicarboxylato)platinum(II). *Cancer Res.* 49: 6629, 1989.

Montine, T.J. and Borch, R.F. Role of endogenous thiols in an in vitro model of cis-diamminedichloroplatinum(II) induced nephrotoxicity. *Biochem. Pharmacol.* 39: 1751, 1990.

Schmalbach, T.K. and Borch, R.F. Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity. *Cancer Res.* 50: 6218, 1990.

Berry, J.M., Jacobs, C., Sikic, B., Halsey, J., and Borch, R.F. Modification of cisplatin toxicity with diethyldithiocarbamate. *J. Clin. Oncol.* 8: 1585, 1990.

Borch, R.F. and Montine, T.J. Renal toxicity of antineoplastic agents. *Toxicol. Lett.* 53: 93, 1990.

Fries, K.M. and Borch, R.F. ³¹P NMR and chloride ion kinetics of monoester phosphoramidates. *J. Med. Chem.* 34: 565, 1991.

Firestone, A.F., Mulcahy, R.T., and Borch, R.F. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. *J. Med. Chem.* 34: 2933, 1991.

Borch, R.F. and Canute, G.W. Synthesis and antitumor properties of activated cyclophosphamide analogs. *J. Med. Chem.* 34, 3044, 1991.

Borch, R.F. and Valente, R.R. Synthesis, activation, and cytotoxicity of aldophosphamide analogs. *J. Med. Chem.* 34, 3052, 1991.

Borch, R.F. The nephrotoxicity of antineoplastic drugs. In: R. Goldstein and J.B. Hook, Eds., Toxicology of the Kidney, pp. 283-301. New York: Raven Press, 1992.

East, C.J., Abboud, C.N., and Borch, R.F. Diethyldithiocarbamate induction of cytokine release in human long-term bone marrow cultures. *Blood* 80, 1172, 1992.

East, C.J. and Borch, R.F. The importance of schedule on diethyldithiocarbamate modulation of drug-induced myelosuppression. *Cancer Chemother. Pharmacol.* 31, 123, 1992.

Borch, R.F. The nephrotoxicity of anticancer drugs. In: M.W. Anders, W. DeKant, D. Henschler, H. Oberleithner, and S. Silbernagl, Eds., Renal Disposition and Nephrotoxicity of Xenobiotics, pp. 289-310. Academic Press, San Diego, 1993.

Mulcahy, R.T., Gipp, J.J., Schmidt, J.P., Joswig, C. and Borch, R.F. Nitrobenzyl phosphoramidates as potential hypoxia-selective alkylating agents. *J. Med. Chem.* 37, 1610, 1994.

Patil, R.R. and Borch, R.F. Granulocyte-macrophage colony-stimulating factor expression by human fibroblasts is both upregulated and subsequently downregulated by Interleukin-1. *Blood* 85, 80, 1995.

Fries, K.M., Joswig, C., and Borch, R.F. Synthesis and biological evaluation of 5-Fluoro-2'-deoxyuridine phosphoramidate analogs. *J. Med. Chem.* 38, 2672, 1995.

Morgan, A.S., Sanderson, P.E., Borch, R.F., Tew, K.D., Niitsu, Y., Takayama, T., Von Hoff, D.D., Izbicka, E., Mangold, G., Paul, C., Broberg, U., Mannervik, B., Henner, D.W. and Kauvar, L.M. Tumor efficacy and bone marrow sparing properties of TER286, a cytotoxin activated by glutathione transferase. *Cancer Res.* 58, 2568, 1998.

Kennedy, S.M. and Borch, R.F. IL-1 α mediates DDTC-induced G-CSF production and hematopoiesis. *Exp. Hematol.* 27, 210, 1999.

Borch, R.F., Liu, J., Schmidt, J.P., Marakovits, J.T., Joswig, C., Gipp, J.J. and Mulcahy, R.T. Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents. *J. Med. Chem.* 43, 2258, 2000.

Flader, C., Liu, J. and Borch, R.F. Development of Novel Quinone Phosphorodiamidate Prodrugs Targeted to DT-diaphorase. *J. Med. Chem.* 43, 3157, 2000.

Meyers, C.L.F., Hong, L., Joswig, C. and Borch R.F. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs. *J. Med. Chem.* 43, 4313, 2000.

Meyers, C.L.F. and Borch, R.F. Activation mechanisms of nucleoside phosphoramidate prodrugs. *J. Med. Chem.* 43, 4319, 2000.

Borch, R.F., Liu, J., Joswig, C., Baggs, R.B., Dexter, D. and Mangold, G. Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. *J. Med. Chem.* 44, 74, 2001.

Steinberg, G. and Borch, R.F. Synthesis and evaluation of pteric acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. *J. Med. Chem.* 44, 69, 2001.

Tobias, S.C. and Borch, R. F. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. *J. Med. Chem.* 44: 4475, 2001.

Meyers, C. L. F. and Borch, R. F. A novel method for the preparation of nucleoside diphosphates. *Org. Lett.* 3, 3765, 2001.

Hernick, M., Flader, C. and Borch, R. F. Design, synthesis and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. *J. Med. Chem.* 45: 3540, 2002.

Hernick, M. and Borch, R. F. Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs. *J. Med. Chem.* 46: 148, 2003.

Meyers, C. L. F. and Borch, R. F. A novel method for the immobilization of nucleotides. *Org. Lett.* 5: 341, 2003.

Tobias, S. C. and Borch, R. F. Synthesis and biological evaluation of a cytosine arabinoside phosphoramidate prodrug. *Molecular Pharmaceutics* 1: 112, 2004.

Wu, W., Freil Meyers, C. L., and Borch, R. F. A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. *Org. Lett.* 6: 2257, 2004.

Wu, W. and Borch, R. F. Synthesis and Biological Activity of *N*-2,3-dihydroxypropyl-*N*-4-chlorobutyl Nucleoside Phosphoramidate Prodrugs. *Mol. Pharmaceutics* 3: 451, 2006.

Garrido-Hernandez, H., Moon, K. D., Geahlen, R. L., and Borch, R. F. Design and synthesis of phosphotyrosine peptidomimetic prodrugs. *J. Med. Chem.* 49: 3368 (2006).

Dilworth, J. T., Kraniak, J. M., Wojtkowiak, J. W., Gibbs, R. A., Borch, R. F., Tainsky, M. A., Reiners, Jr., J. J., Mattingly, R. R. Molecular Targets for Emerging Anti-Tumor Therapies for Neurofibromatosis Type 1. *Biochem. Pharmacol.* 72: 1485 (2006).

Choi, J. Y. and Borch, R. F. Highly efficient synthesis of enantiomerically enriched 2-hydroxymethylaziridines by enzymatic desymmetrization. *Org. Lett.* 9: 215 (2007).

Boutselis, I. G., Yu, Z., Zhang, Z.-Y. and Borch, R. F. Synthesis and cell-based activity of a potent and selective PTP1B inhibitor prodrug. *J. Med. Chem.* 50: 856 (2007)

Clark, M. K., Reigard, S. A., Wojtkowiak, J., Chirco, R., Mathieu, P., Reiners, J. J. Jr., Mattingly, R. R., Borch, R. F., and Gibbs, R. A. Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase Inhibitors. *J. Med. Chem.* 50: 3274 (2007).

Wu, W., Sigmond, J., Peters, G. J., and Borch, R. F. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. *J. Med. Chem.* 50: 3743 (2007).

Wojtkowiak, J. W., Fouad, F., LaLonde, D. T., Kleinman, M. D., Gibbs, R. A., Reiners, J. J. Jr., Borch, R. F. and Mattingly, R. R. Induction of apoptosis in Neurofibromatosis Type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. *J. Pharmacol. Exp. Ther.* 326: 1 (2008).

Luo, M., Delaplane, S., Jiang, A., Reed, A., He, Y., Fishel, M., Nyland II, R.L., Borch, R.F., Qiao, X., Georgiadis, M. M. and Kelley, M. R. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: Small molecule inhibition of Ape1's redox function. *Antioxid. & Redox Signal.* 10: 1853 (2008).

Sane, K. |M., Maynor, M., LaLonde, D. T., Dean, I. S., Wojtkowiak, J. W., Fouad, F., Borch, R. F., Reiners, J. J. Jr., and Gibbs, R. A. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. *J. Pharmacol. Exp. Ther.* 333: 23 (2010).

Nyland II, R. L., Luo, M., Kelley, M. R. and Borch, R. F. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/ apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/Ref-1). *J. Med. Chem.* 53: 1200 (2010).

Kelley, M. R., Luo, M., Reed, A., Su, D., Delaplane, S., Borch, R., Nyland II, R. L., Gross, M., and Georgiadis, M. Functional analysis of novel analogs of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. *Antioxid. Redox Signal.* 2010, 12, (Epub ahead of print).